Yazar "Taner M." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Clinical evaluation of metastases of malignant melanoma imaging with99Tcm-glutathione and99Tcm-anti-melanoma antibody: A comparative study
    (1995) Duman Y.; Burak Z.; Ercan M.T.; Dirlik A.; Bilkay B.; Akin Y.; Taner M.; Bekdik C.F.
    The aim of this investigation was to test for the scintigraphic detection of metastases of malignant melanoma with a new radiopharmaceutical,99Tcm-glutathione (99Tcm-GSH), in comparison with99Tcm- anti-melanoma antibody (99Tcm-AMAb). Glutathione was labelled with99Tcmby a Sn2+reduction method with an efficiency of > 99% as determined by instant thin layer chromatography (ITLC). Anti-melanoma antibody was obtained as a kit from SORIN (Italy) and labelled with99TcmO4. Forty-three patients with a total of 55 biopsy-proven metastatic melanoma foci, 1 ocular melanoma and 20 benign pathologic foci, also confirmed by ultrasound, computed tomography and magnetic resonance imaging, were included in the study after giving their informed consent. Following the intravenous (i.v.) injection of 500 MBq99Tcm-AMAb, scintigraphic images of the involved areas were obtained 6 h post-injection. Three days later, the same patients were given 500 MBq99Tcm-GSH i.v. and images were obtained 6 and 24 h post-injection. The images were classified as positive (focal abnormal accumulation) or negative. Quantitative evaluation was also applied. Regions of interest were drawn over the involved areas and nearby soft tissues and the target-to- nontarget (T/NT) ratios obtained with99Tcm-AMAb (T/NT: 1.92 ± 0.2) and99Tcm-GSH (T/NT: 1.84 ± 0.2) were compared (0.1 < P < 0.3). The sensitivity (and specificity) of99Tcm-AMAb and99Tcm-GSH in the detection of malignant melanoma metastases were 91% (95%) and 84% (90%), respectively. Compared with99Tcm-AMAb, the advantages of99Tcm-GSH are lower levels of blood radioactivity, lower costs and easy in-house preparation. In conclusion, our results show that99Tcm-GSH is a potentially useful radio-pharmaceutical for the detection of metastases of malignant melanoma. © 1995 Chapman and Hall Ltd.
  • Küçük Resim Yok
    Öğe
    Detection of metastatic bone lesions in patients with prostate carcinoma 99tcm-monoclonal antibody imaging
    (1997) KiraÇ S.; Duman Y.; CÜreklibatur I.; YÜksel D.; Nazli O.; GÜnaydin G.; Taner M.
    Bone scintigraphy has been shown to be sensitive in determining bone involvement in patients with malignancy, but it does not allow the assessment of bone marrow lesions in early disease. The aim of this study was to detect bone marrow invasion using 99Tcm-labelled monoclonal antigranulocyte antibody (AgMoAb) in patients with prostate carcinoma. We studied 56 patients whose mean (± S.D.) age was 67 ± 7 years. The mean prostate-specific antigen level was 6.1 ng ml-1 (normal range 0-5 ng ml 1). Twelve patients were in stage A, 16 in stage B, 17 in stage C and 11 in stage D. Six patients had been receiving chemotherapy and four patients radiotherapy before scanning. Bone scans were obtained 2 h after the intravenous injection of 555 MBq 99Tcm-methylene diphosphonate (99Tcm-MDP). Within a week, bone marrow imaging was performed 4 and 24 h after the injection of 555 MBq 99Tcm-AgMoAb. Metastatic bone lesions were detected on the 99Tcm-MDP scans of 14/56 (25%) patients, of whom one was in stage A, two in stage B, four in stage C and seven in stage D. Hypoactive lesions in bone marrow were detected in 25/56 (45%) patients, of whom two were in stage A, five in stage B, seven in stage C and 11 in stage D. Bone marrow metastases were confirmed in six patients by computed tomography (CT) and magnetic resonance imaging (MRI) and in two patients by marrow aspiration biopsy. A false-positive immune scintigram was found in three patients previously receiving radiotherapy or chemotherapy. We suggest that 99Tcm-AgMoAb scintigraphy is a sensitive procedure for the detection of bone marrow lesions. However, the reason for false-positive and false-negative results should be considered and CT, MRI and marrow biopsy should be performed when clinically necessary. © 1997 Chapman and Hall Ltd.
  • Küçük Resim Yok
    Öğe
    Radioisotope synovectomy with rhenium186 in haemophilic synovitis for elbows, ankles and shoulders
    (2008) Kavakli K.; Aydogdu S.; Taner M.; Duman Y.; Balkan C.; Karapinar D.Y.; Saydam, G..; Capaci K.; Oktay A.
    We have performed 221 radioisotope synovectomy (RS) in more than 150 children and young adults with haemophilia, age ranging 3-30years (mean 15) in Ege Hemophilia Center, Izmir, Turkey for last 7years. We always preferred to use Yttrium 90 (Y90) for knees; however, since 2005, we started using rhenium 186 (Re186) for medium-sized joints with respect to safety. In this article, we have evaluated long-term experience ranging from 6months to 3years (mean 18months) with Re186 for elbows (n = 35), ankles (n = 26) and shoulders (n = 2) in total of 63 RS procedures for 49 patients. Their age range was 3-30 years and mean age was 15.5. Two mCi of Re186 intra-articularly injected for treating target joints and chronical synovitis. After RS, joint bleedings were decreased for all patients. The best results were obtained for all joints in patients with grade-II synovitis as like earlier experience with Y90. Excellent rates (no bleeding) were observed in grade-II synovitis in 81% and 46% for elbows vs. 86% and 57% for ankles after 6months and after 1 year follow-up of patients, respectively. In grade-III synovitis, excellent rates were 53% and 25% for elbows and 44% and 29% for ankles, respectively. In five joints for five patients, repeated injections were needed for better outcome. No adverse events such as radioisotope leakage, local inflamatory reactions or malignancy development were observed during and after RS. For medium-sized joints, RS with Re186 seems to be either effective or safe treatment method. Our results confirm those previously published by others on the value of Re186 synoviorthesis in medium-sized joints in haemophilia patients. After this experience, we changed our protocol and we use Re 186 for all medium-sized joints for treating chronical synovitis. © 2008 Blackwell Publishing Ltd.